Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
23 October 2023 - 10:00PM
via NewMediaWire -- Aclarion, Inc.,
(“Aclarion” or the
“Company”) (Nasdaq: ACON, ACONW), a
healthcare technology company that is leveraging biomarkers and
proprietary augmented intelligence algorithms to help physicians
identify the location of chronic low back pain, announced today
that the Company has executed a non-binding Letter of Intent
(“LOI”) to form a strategic partnership with ATEC Spine, Inc., the
wholly owned operating subsidiary of Alphatec Holdings, Inc.
(Nasdaq: ATEC).
Uniting the unique structural data powered by ATEC’s
AlphaInformatiX, with the innovative biomarker data that enables
Aclarion’s Nociscan solution to identify each disc as painful or
not, will provide surgeons with unprecedented data across one
platform. The platform is designed to improve clinical outcomes
while reducing overall procedural costs for patients with chronic
back pain.
Pat Miles, CEO of ATEC, commented, “Evolving spinal technologies
through innovation requires discipline, time, know-how, and
resources. This partnership with Aclarion reflects our belief in
the importance of biochemical markers within the treatment
paradigm. Nociscan is exactly the type of innovation that can
advance our shared goal of integrating and advancing technologies
that improve the predictability and reproducibility of spine
care.”
Aclarion’s proprietary decision-support tool, Nociscan, is the
first evidence-supported SaaS platform to noninvasively help
physicians distinguish between painful and nonpainful discs in the
lumbar spine. Nociscan objectively quantifies chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to highlight if a disc may be a
source of pain. When used with other diagnostic tools, Nociscan
provides critical insights into the location of a patient’s low
back pain, giving physicians clarity to optimize treatment
strategies.
Aclarion’s published trials confirm the comparative advantage of
Nociscan in achieving differentiated surgical outcomes. In April
2023, Aclarion announced a published, peer-reviewed, 85% success
rate at 2 years for discogenic low back pain surgeries for patients
whose treatment strategy was consistent with Nociscan-identified
discs. This result was a 22-percentage point improvement over
patients whose treatment strategy was inconsistent with
Nociscan-identified discs (85% vs. 63%; p=0.07).1
1 https://pubmed.ncbi.nlm.nih.gov/37014434/
“We share a common vision with ATEC regarding the value of
advanced decision support information to improve patient care. This
strategic partnership is a significant milestone for Aclarion. Pat
and the ATEC team are revolutionizing spine surgery, and we
appreciate their endorsement,” said Brent Ness, CEO of
Aclarion.
The LOI contemplates a multi-step strategic partnership. Under
the LOI, ATEC and Aclarion will work together to identify Key
Opinion Leader (KOL) surgeons to evaluate Nociscan technology.
Feedback from these surgeons will inform clinical evaluations
designed to assess the utility of Nociscan in conjunction with EOS
imaging, the foundation of ATEC’s AlphaInformatiX platform.
Assuming positive synergies, ATEC and Aclarion will co-market
Nociscan in targeted markets. In exchange for select access to
ATEC’s surgeon network for the evaluation and advancement of
Nociscan, Aclarion will provide ATEC with certain exclusive
distribution rights to include Nociscan as part of an integrated
procedural solution.
Chronic low back pain (cLBP) is a global healthcare problem with
approximately 266 million people worldwide suffering from
degenerative spine disease and low back pain. Conventional imaging
and diagnostics provide valuable structural information
but are limited in identifying the source of the pathogenic
pain.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages
Magnetic Resonance Spectroscopy (“MRS”), proprietary signal
processing techniques, biomarkers, and augmented intelligence
algorithms to optimize clinical treatments. The Company is first
addressing the chronic low back pain market with Nociscan, the
first, evidence-supported, SaaS platform to noninvasively help
physicians distinguish between painful and nonpainful discs in the
lumbar spine. Through a cloud connection, Nociscan receives
magnetic resonance spectroscopy (MRS) data from an MRI machine for
each lumbar disc being evaluated. In the cloud, proprietary signal
processing techniques extract and quantify chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to indicate if a disc may be a
source of pain. When used with other diagnostic tools, Nociscan
provides critical insights into the location of a patient’s low
back pain, giving physicians clarity to optimize treatment
strategies. For more information, please visit
www.aclarion.com.
About ATEC
Alphatec Holdings, Inc., through its
wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.
and SafeOp Surgical, Inc., is a medical device company dedicated to
revolutionizing the approach to spine surgery through clinical
distinction. ATEC’s Organic Innovation MachineTM is focused on
developing new approaches that integrate seamlessly with the
Company’s expanding AlphaInformatiX Platform to better inform
surgery and more safely and reproducibly achieve the goals of spine
surgery. ATEC’s vision is to be the Standard Bearer in Spine. For
more information, visit us at www.atecspine.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 about the Company's current
expectations about future results, performance, prospects and
opportunities. Statements that are not historical facts, such as
"anticipates," "believes" and "expects" or similar expressions, are
forward-looking statements. These forward-looking statements are
based on the current plans and expectations of management and are
subject to a number of uncertainties and risks that could
significantly affect the Company's current plans and expectations,
as well as future results of operations and financial condition.
These and other risks and uncertainties are discussed more fully in
our filings with the Securities and Exchange Commission. Readers
are encouraged to review the section titled "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended December
31, 2022, as well as other disclosures contained in the Prospectus
and subsequent filings made with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Disclosure
The information stated above was prepared by Aclarion and
reflects solely the opinion of Aclarion. Nothing in this statement
shall be construed to imply any support or endorsement of Aclarion
or any of its products by ATEC.
Investor Contacts:Kirin M. SmithPCG Advisory,
Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG
Consulting612.812.7477jodi@sprigconsulting.com
Aclarion (NASDAQ:ACONW)
Historical Stock Chart
From Apr 2024 to May 2024
Aclarion (NASDAQ:ACONW)
Historical Stock Chart
From May 2023 to May 2024